Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277270 · ClinicalTrials.gov registry record · Phase 1
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 6
- Study locations
NCT07277270 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 84 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT07277270, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Fluorouracil
- DRUG Enzalutamide
- DRUG GSK5764227
- DRUG leucovorin
Study Locations (6)
Other
- GSK Investigational Site - Barcelona
- GSK Investigational Site - Madrid
- GSK Investigational Site - Madrid
- GSK Investigational Site - Málaga
New York
- GSK Investigational Site - Lake Success
Queensland
- GSK Investigational Site - Tugun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277270
The ClinicalTrials.gov registry entry for NCT07277270 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07277270 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Queensland.
Frequently Asked Questions
What is clinical trial NCT07277270 about?
NCT07277270 is a clinical study titled "A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors". The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it ...
What is the current status of trial NCT07277270?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2025-12-03. Estimated completion is 2028-09-29.
What conditions does trial NCT07277270 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT07277270?
The interventions under investigation include: Bevacizumab (DRUG), Fluorouracil (DRUG), Enzalutamide (DRUG), GSK5764227 (DRUG), leucovorin (DRUG).
Who is sponsoring clinical trial NCT07277270?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277270 being conducted?
This trial has 6 study locations across New York, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.